Mineralys Therapeutics Inc (NASDAQ: MLYS) is 21.53% higher on its value in year-to-date trading and has touched a low of $8.24 and a high of $18.38 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MLYS stock was last observed hovering at around $14.21 in the last trading session, with the day’s gains setting it 0.75%.
Currently trading at $14.96, the stock is 12.10% and 14.14% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing 5.28% at the moment leaves the stock 21.31% off its SMA200. MLYS registered 20.94% gain for a year compared to 6-month loss of 7.70%. The firm has a 50-day simple moving average (SMA 50) of $13.1062 and a 200-day simple moving average (SMA200) of $12.33215.
The stock witnessed a 8.09% gain in the last 1 month and extending the period to 3 months gives it a 45.67%, and is 6.17% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.14% over the week and 8.93% over the month.
Mineralys Therapeutics Inc (MLYS) has around 51 employees, a market worth around $970.55M and $0.00M in sales. Distance from 52-week low is 81.53% and -18.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-92.97%).
The EPS is expected to shrink by -2.23% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
159.0 institutions hold shares in Mineralys Therapeutics Inc (MLYS), with institutional investors hold 81.86% of the company’s shares. The shares outstanding are 49.82M, and float is at 38.02M with Short Float at 16.02%. Institutions hold 80.66% of the Float.
The top institutional shareholder in the company is CATALYS PACIFIC, LLC with over 9.19 million shares valued at $107.58 million. The investor’s holdings represent 18.629 of the MLYS Shares outstanding. As of 2024-06-30, the second largest holder is SAMSARA BIOCAPITAL, LLC with 5.07 million shares valued at $59.38 million to account for 10.2822 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 4.85 million shares representing 9.8285 and valued at over $56.76 million, while TCG CROSSOVER MANAGEMENT, LLC holds 6.4535 of the shares totaling 3.19 million with a market value of $37.27 million.
Mineralys Therapeutics Inc (MLYS) Insider Activity
The most recent transaction is an insider purchase by Slingsby Brian Taylor, the company’s Director. SEC filings show that Slingsby Brian Taylor bought 259,259 shares of the company’s common stock on Mar 13 ’25 at a price of $13.50 per share for a total of $3.5 million. Following the purchase, the insider now owns 8.9 million shares.
Mineralys Therapeutics Inc disclosed in a document filed with the SEC on Apr 14 ’25 that Rodman David Malcom (Chief Medical Officer) sold a total of 11,366 shares of the company’s common stock. The trade occurred on Apr 14 ’25 and was made at $14.53 per share for $0.17 million. Following the transaction, the insider now directly holds 0.11 million shares of the MLYS stock.
Still, SEC filings show that on Apr 11 ’25, Levy Adam Scott (CFO and Secretary) disposed off 10,757 shares at an average price of $12.06 for $0.13 million. The insider now directly holds 215,340 shares of Mineralys Therapeutics Inc (MLYS).
